Normalized administered atezolizumab dose and clinical outcomes in advanced solid tumors: an exploratory analysis of the phase I PCD4989g study.
- DOI
- 10.1016/j.iotech.2026.101612
- Published
- 2026 Dec
- Container
- Immuno-oncology technology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.iotech.2026.101612,
title = {Normalized administered atezolizumab dose and clinical outcomes in advanced solid tumors: an exploratory analysis of the phase I PCD4989g study.},
author = {Moreno V and Dorta M and Rueda A and Villalba P and García-Lorenzo E and Pedregal M and Doger B and Mahíllo-Fernández I},
year = {2026},
journal = {Immuno-oncology technology},
doi = {10.1016/j.iotech.2026.101612},
url = {https://doi.org/10.1016/j.iotech.2026.101612}
}RIS
TY - JOUR TI - Normalized administered atezolizumab dose and clinical outcomes in advanced solid tumors: an exploratory analysis of the phase I PCD4989g study. AU - Moreno V AU - Dorta M AU - Rueda A AU - Villalba P AU - García-Lorenzo E AU - Pedregal M AU - Doger B AU - Mahíllo-Fernández I PY - 2026 JO - Immuno-oncology technology DO - 10.1016/j.iotech.2026.101612 UR - https://doi.org/10.1016/j.iotech.2026.101612 ER -
APA
V, M., M, D., A, R., P, V., E, G., M, P., B, D., & I, M. (2026). Normalized administered atezolizumab dose and clinical outcomes in advanced solid tumors: an exploratory analysis of the phase I PCD4989g study.. Immuno-oncology technology. https://doi.org/10.1016/j.iotech.2026.101612
Source records
- pubmed · retrieved 2026-11-10T11:34:22.261Z